China Resources Double-Crane: Shuanghe Xiangzhong Brexpiprazole API Approved for Registration on September 21, 2026

China Resources Double-Crane announced that its controlling subsidiary, China Resources Double-Crane Xiangzhong Pharmaceutical Co., Ltd., submitted a marketing application for brexpiprazole API on March 7, 2025, and obtained CDE public registration on March 13, 2025; on September 21, 2026, it obtained the "Chemical API Marketing Application Approval Notice" issued by the National Medical Products Administration, with the approval conclusion being approval for registration. After passing the GMP compliance inspection, it may be produced and sold in the domestic market. The cumulative R&D investment was 9.6987 million yuan.